Antibiotic Resistant Bacterial Pathogens Associated with Blood Stream Infections and Urinary Tract Infections among Intensive Care Unit Patients

Shriram Dorairaj Gunasekaran¹, Godfred Antony Menezes²*, Rezmitha Zulfihar Nazeem¹, Mohammad Obada Sultan¹, Tejaswini Archarya¹, Shaista Khadim¹, Resshme Kannan Sudha¹, Harshita Janardhan¹, Mrinali Sanjay Bhatia¹, Farzeen Fathima¹, Khulood AlKhateri³, Michael Magaogao¹, Sara Babiker Ali³, Hanadi Elias Hassan³, Essam El-Din Mahran Aly³ and Azan Saleh Al Saadi¹,³

¹RAK College of Medical Sciences (RAKCOMS), RAK Medical & Health Sciences University (RAKMHSU), Ras Al Khaimah, UAE.
²Associate Professor & Clinical Microbiologist, RAK College of Medical Sciences (RAKCOMS), RAK Medical & Health Sciences University (RAKMHSU), Ras Al Khaimah, UAE.
³Saqr Hospital, Ras Al Khaimah, UAE.

Abstract

Blood Stream Infection (BSI) and Urinary Tract Infection (UTI) being leading causes of morbidity and mortality represent a common complication among critically ill patients. During the last decade, clinicians have observed a rising occurrence of BSIs due to bacterial resistance. Likewise, catheter-associated UTI is a main cause of morbidity and mortality affecting all age groups. Coliforms happen to be the prominent pathogens among our ICU admitted patients. It was alarming to notice 42.9% resistance to tigecycline among 
K. pneumoniae
isolated from blood. 
K. pneumoniae
isolates cultured from urine of ICU patients uniformly displayed 75% resistance to ciprofloxacin, ceftriaxone, cefoxitin and cefepime. Interestingly, it is of respite to observe 85.7% 
K. pneumoniae
isolated from blood and 75% 
K. pneumoniae
isolated from urine being susceptible to a conventional antibiotic, gentamicin. 
Escherichia coli
isolated from urine were 100% susceptible to carbapenems and 91.75% were susceptible to tigecycline. Overall, 90% of 
Pseudomonas aeruginosa
were susceptible to nitrofurantoin. The rapid spread of these MDR pathogens demands for national and regional guidelines. Policies to treat ICU related infections in UAE should be designed based on local microbiological data and resistance profiles of pathogens.

Keywords: Antimicrobial Resistance, pathogens, Blood Stream Infections, Urinary Tract Infections, Intensive Care Unit Patients

© The Author(s) 2020. Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License which permits unrestricted use, sharing, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
INTRODUCTION

In spite of controlling many risk factors, there is higher risk of infections in intensive care units (ICUs) compared with regular wards. In comparison to pneumonia and wound infections, BSI and UTI have a higher incidence in ICUs compared with other wards. Patients should be managed in ICUs for an optimal period that is necessary for their care. Effective and prompt antibiotic therapy is necessary in order to improve clinical outcomes and reduce mortality. Nevertheless, due to worldwide spread of multi-drug resistant (MDR) organisms, the choice of empiric antibiotic regimen is often challenging. We need to have new therapeutic challenges to minimize the risk of resistance selection in turn to improve the effectiveness of antibiotic treatment. BSIs form leading infections among critically ill patients. The case-fatality rate related to BSIs in patients admitted to ICUs is very high (35-50%). Antimicrobial therapy is the cornerstone for treating BSIs, which are solely responsible for leading into severe sepsis and septic shock. During the last decade, clinicians have observed a rising occurrence of BSIs by bacteria resistant to commonly used antimicrobials. A MDR microorganism is resistant to at least one agent in three or more antimicrobial classes. Extensive drug-resistant (XDR) microorganisms is susceptible to only one or two antimicrobial classes, while pan-DR (PDR) isolates are resistant to all agents from all antimicrobial classes. Emergence of antibiotic resistance is a global public health problem. Likewise, catheter-associated UTI is a main cause of morbidity and mortality affecting all age groups. Bacteriuria or candiduria is nearly unavoidable in half of the patients on indwelling urinary catheter for more than five days. Patients with asymptomatic bacteriuria harbor major pool of antibiotic resistant pathogens in hospitals. With this background in mind, we designed this study with the following aim: to study the prevalence of BSI and UTI causing pathogens from ICU in past 2 years.

MATERIALS AND METHODS

It is a cross-sectional and retrospective study. The bacterial isolates from patients with BSIs and UTIs, who were admitted in ICUs of a tertiary care hospital (ICUs of Saqr Hospital, Ras Al Khaimah, UAE) of a 2 years period (2016 and 2017) were included. Institutional Ethical Clearance and regional ethical clearance (2018) approval has been obtained for the study.

Bacterial isolation, identification and antibiotic susceptibility testing

Both Gram positive and Gram-negative bacteria isolated from blood and urine of patients suffering from BSIs and UTIs respectively were included. Bacterial identification and antibiotic susceptibility testing (Minimum Inhibitory Concentration- MIC based) were performed using Vitek 2 (bioMerieux Inc., Durham, NC). The Vitek panel preparation had included QC strains as recommended by Clinical & Laboratory Standards Institute (CLSI) guidelines. The following antibiotics were included in the susceptibility testing – ampicillin (A), ciprofloxacin (Cf), clindamycin (Cd), doxycycline (Do), erythromycin (E), levofoxacin (Lf), linezolid (Lz), moxifloxacin (Mf), nitrofurantoin (Nf), tetracycline (T), tigecycline (Tg), vancomycin (Va), Oxacillin (Ox) amoxicillin/clavulanate (AC), Cefoxitin (Cn), ceftriaxone (Ci), gentamicin (G), Tigecycline (Tg), aztreonam (Az), cefepime (Cp), ceftazidime (Ca), colistin (Cl), imipenem (Im), meropenem (Mm), minocycline (Mc), pefloxacin (Pf), pipercillin (Pc), piperacillin/tazobactam (PT), rifampin (Rf), ticarcillin (Tc), tobramycin (Tb), trimethoprim/sulfamethoxazole (TS) and amikacin (Ak).

Statistical analysis of data

Data on the prevalence of drug resistance in bacterial pathogens causing BSIs and UTIs in patients admitted to ICUs was obtained and statistically analyzed using GraphPad prism 7.0.

RESULTS

Totally 79 patients with either BSI or UTI, or both, were admitted in ICU; during the years 2016 and 2017 were included. From the blood and/or urine of these patients, one or more bacterial strains were cultured.

Distribution of BSI and UTI among patients in ICU

A total 111 bacterial cultures were obtained from blood or urine of the 79 patients
admitted in the ICU. Of 111 bacterial cultures, 73 (65.8%) were from urine (UTIs) and 38 (34.2%) were from blood (BSIs).

**Statistical significance between the BSIs and UTIs in 2017 when compared to 2016**

There was a decrease in both BSIs and UTIs in 2017 when compared to 2016. By using Fisher’s exact test, it was found that the two-tailed P value is less than 0.0001. The association between infections (BSIs and UTIs) and years (2016, 2017) is considered extremely statistically significant.

**Distribution of bacterial pathogens among BSIs**

Totally 38 bacterial strains were isolated and identified from blood, of patients admitted in the ICU, by the Vitek 2 (bioMérieux Inc., Durham, NC) system. Among the Gram-positive bacteria, 13 isolates of coagulase negative *Staphylococcus*, 2 isolates of *Enterococcus faecalis* and one each of *Staphylococcus aureus*, *Enterococcus faecium*, and *Leuconostoc citreum* were obtained. Among Gram-negative bacteria, 10 isolates of *Klebsiella pneumoniae*, 2 isolates of *E. coli* and one each of *Pseudomonas aeruginosa* and *Klebsiella oxytoca* were obtained. Six isolates of *Candida* spp. were also obtained (Fig. 1).

**Distribution of bacterial pathogens among UTIs**

A total of 73 bacterial strains were isolated and identified from urine, of patients admitted in the ICU, by the Vitek 2 (bioMerieux Inc., Durham, NC) system. Among Gram negative bacteria, 16 isolates of *Acinetobacter baumannii*, 14 isolates of *E. coli*, 14 isolates of *Klebsiella pneumoniae*, 12 isolates of *Pseudomonas aeruginosa*, 3 isolates of
Fig. 3. Antimicrobial susceptibility trend of *Klebsiella pneumoniae* cultured from blood of ICU patients (2016-2017)

Fig. 4. Antimicrobial susceptibility trend of *Escherichia coli* cultured from urine of ICU patients (2016-2017)

Fig. 5. Antimicrobial susceptibility trend of *Pseudomonas aeruginosa* cultured from urine of ICU patients (2016-2017)
Enterobacter cloacae, 3 isolates of unidentified Gram negative rods, and one each of Klebsiella ozaenae, Proteus mirabilis, Serratia marcescens were obtained. Among Gram positive bacteria 4 isolates of Enterococcus faecalis and 4 isolates of Candida spp. were obtained (Fig. 2).

Antimicrobial susceptibility pattern of isolates cultured from blood of ICU patients

Among Klebsiella pneumoniae, the resistance rate of 85.7% was observed against ampicillin and ceftriaxone. The isolates of Klebsiella pneumoniae were uniformly resistant (50 - 75% resistant) to range of antibiotics tested amikacin, ceftazidime, ciprofloxacin, cefepime, nitrofurantoin, imipenem, meropenem and β-lactam plus β-lactamase inhibitor combinations. Interestingly, 85.7% Klebsiella pneumoniae were susceptible to a conventional antibiotic, gentamicin. It was alarming to notice 42.9% resistance to tigecycline (Fig. 3 and Table 1).

Antimicrobial susceptibility trend of isolates cultured from urine of ICU patients

Escherichia coli isolated from urine were 100% susceptible to carbapenems (imipenem and
isolates ranged 50-75% in resistance to array of antibiotics tested. Of the isolates, 91.75% were susceptible to tigecycline (Fig. 4 and Table 2).

**Pseudomonas aeruginosa** isolates cultured from urine of ICU patients were 100% resistant to ampicillin, amoxicillin-clavulanate, ceftaxime, cefoxitin, and trimethoprim-sulphamethoxazole. Interestingly, 100% isolates were susceptible to gentamicin and 90% were susceptible to cefepime and nitrofurantoin. For other range of antibiotics tested, the resistance rate varied from 50% to 75% (Fig. 5 and Table 2).

**Klebsiella pneumoniae** isolates cultured from urine of ICU patients uniformly displayed 75% resistance to ciprofloxacin, trimethoprim-sulphamethoxazole, ceftazidime, ceftriaxone, cefoxitin, cefepime, amoxiclave and piperacillin-tazobactam. Overall, 87.5% of *K. pneumoniae* were resistant to nitrofurantoin. Further, 75% of *K. pneumoniae* were susceptible to gentamicin. (Fig. 6 and Table 2).

**Acinetobacter baumannii complex** cultured from urine of ICU patients displayed an alarmingly high rate of consistent resistance to all the antibiotics tested. Further, up to 50% of the isolates were susceptible to gentamicin and up to 75% of the isolates were susceptible to tigecycline (Fig. 7 and Table 2).

**DISCUSSION**

Infection surveillance is vital for quality care, prevention, and suitable management of ICU-acquired infections. Occurrence of ICU-acquired infections vary in different settings - ICU types and type of population\(^{13}\). Knowledge about prominent pathogens in ICU acquired infections and their resistance profile can help us frame specific infection control policies and avoid spread of such infections.

Rosental *et al.*, in their multi centric study demonstrated the following prevalent type of infections - ventilator-associated pneumonia (41%), BSIs (30%) and urinary tract infections (29%)\(^{14}\). In the present study, a total 111 bacterial cultures were obtained from blood or urine of the 79 patients admitted in the ICU. Of 111 bacterial cultures, 73 (65.8%) were from urine (UTIs) and 38 (34.2%) were from blood (BSIs) Habibi *et al.*, in a study on nosocomial infections found UTI in 24%, and BSI in 24% subjects\(^{15}\). United States National Nosocomial Infections Surveillance data showed UTIs in 23% and BSIs in 14% subjects\(^{16}\). Kamat *et al.*, showed UTI (26.6%) to be the most common infection in ICU set up\(^{17}\).

Several studies have observed that Gram-negative pathogens are the main cause of nosocomial infections, which is in concordance with our study\(^{16,17}\). In our study, among the isolates
| S. No. | Gender | Isolate            | Susceptible to                                                                 | Resistant to                                                                 |
|-------|--------|--------------------|-------------------------------------------------------------------------------|------------------------------------------------------------------------------|
| 1     | Male   | *Staphylococcus hominis* | Cf, Cd, G, Lf, Lz, Mf, Tg, Va                                                | E, Ox (Cn screen +), TS, T, Do, Nf                                           |
| 2     | Male   | *Staphylococcus warneri* | Cf, Cd, Do, Nf, G, Lf, Lz, Mf, TS, Tg, Va                                     | E, Ox (Cn screen +)                                                           |
| 3     | Male   | *Pseudomonas aeruginosa* | Ak, Ca, Cf, Cp, G, Mm, PT                                                    | A, AC, Cl, Cn, Nf, TS, Tg, Im                                                |
| 4     | Male   | *Staphylococcus capitis* | Cf, Cd, Do, Nf, Lf, Lz, TS, Mf, T, Tg, Va                                    | E, Ox (Cn screen +), G                                                        |
| 5     | Male   | *Klebsiella pneumoniae* | AC, Ak, Ca, Cf, Cl, Cp, Cn, G, Im, Mm, TS, Tg                                | A, Nf                                                                        |
| 6     | Male   | *Enterococcus faecalis* | A, Cf, Nf, Lf, Lz, Mf, Tg, Va                                               | Cd, Do, E, T                                                                 |
| 7     | Female | *Staphylococcus epidermidis* | Do, Nf, TS, Tg, Va                                                           | Cf, Cd, E, G, Lf, Lz, Mf, Ox (Cn screen +), T                                |
| 8     | Male   | *Staphylococcus capitis* | Cd, Do, Nf, G, Lf, Lz, TS, T, Tg, Va                                        | Cf, E, Lf, Mf, Ox (Cn screen +)                                              |
| 9     | Male   | *Enterococcus faecium*  | Do, Lz, T, Tg                                                                | A, Cf, Cd, E, Nf, Lf, Mf, Va                                                 |
| 10    | Male   | *Citrobacter koseri*    | A, AC, Ak, Ca, Cf, Cl, Cp, Cn, Nf, G, Im, Mm, TS, Tg, PT                     | None                                                                         |
| 11    | Male   | *Leuconostoc citreum*   | Not tested                                                                   | Not tested                                                                   |
| 12    | Male   | *Staphylococcus capitis* | Do, Nf, Lz, TS, T, Tg, Va                                                    | Cf, Cd, E, Lf, Mf, Ox (Cn screen +), G                                        |
| 13    | Male   | *Klebsiella pneumoniae* | Cl, G                                                                        | Ak, Az, Ca, Cf, Cp, Im, Mm, Mc, Pc, Ts, Tc, Tb, PT                           |
| 14    | Male   | *Klebsiella pneumoniae* | G                                                                            | A, AC, Ak, Ca, Cf, Cl, Cp, Cn, Nf, Im, Mm, TS, Tg, PT                        |
| 15    | Male   | *Klebsiella pneumoniae* | G                                                                            | A, AC, Ak, Ca, Cf, Cl, Cp, Cn, Nf, Im, Mm, TS, Tg, PT                        |
| 16    | Male   | *Staphylococcus epidermidis* | Do, Nf, T, Tg, Va                                                             | Cf, Cd, E, G, Lz, Os (Cn screen +), TS, Lf, Mf                              |
| 17    | Female | *Staphylococcus epidermidis* | Cf, Do, E, Nf, G, Lf, Lz, Mf, Ox, TS, T, Tg, Va                              | Cd                                                                           |
| 18    | Male   | *Escherichia coli*      | AC, Ak, Cf, Cl, Cp, Cn, G, Im, Mm, TS, Tg, PT                                | A, Ca, Cl, Cp, Nf                                                            |
| 19    | Female | *Klebsiella pneumoniae* | A, AC, Ak, Ca, Cf, Cl, Cp, Cn, Nf, Mm, Ts, Tg, PT                            | G                                                                            |
| 20    | Male   | *Staphylococcus hominis* | Cf, Cd, Do, E, Nf, G, Lf, Lz, Mf, Ox, TS, T, Tg, Va                          | None                                                                         |
| 21    | Male   | *Klebsiella oxytoca*    | Ak, Cf, Cp, G, Im, Mm, TS, Tg, PT                                            | A, AC, Ca, Cl, Cp, Cn, PT, Nf                                                |
| 22    | Female | *Staphylococcus epidermidis* | Do, Nf, Mf, T, Tg, Va                                                        | Cf, Cd, E, G, Lz, Os (Cn screen +), Lf                                        |
| 23    | Female | *Staphylococcus hominis* | Cf, Cd, Do, E, Nf, G, Lf, Lz, Mf, Ox, TS, T, Tg, Va                          | None                                                                         |
| 24    | Male   | *Escherichia coli*      | Ac, Mk, Nf, Mm, Ts, Tg, Pt                                                    | A, AC, Ca, Cl, Cp, G, Ts                                                     |
| 25    | Male   | *Staphylococcus aureus* | Cf, Cd, Do, E, Nf, G, Lf, Lz, Mf, Ox, TS, T, Tg, Va                          | None                                                                         |
| 26    | Male   | *Staphylococcus epidermidis* | Cf, Cd, Nf, G, Lf, Lz, Mf, Ox, T, Tg, Va                                   | Do, E, TS                                                                    |
| 27    | Male   | *Enterococcus faecalis* | N, Ss, Lz, Tg, Va                                                            | A, Cf, Cd, Do, E, Lf, Mf, T                                                   |
| 28    | Female | *Klebsiella pneumoniae* | Ak, AC, Cl, Cp, G, Im, Mm, Nf, PT                                            | A, Cp, Ca, Cl, TS                                                            |
| 29    | Male   | *Klebsiella pneumoniae* | G, Tg, TS                                                                     | A, Ak, AC, Cp, Cl, Ca, Cl, Cp, G, Im, Mm, Nf, PT                            |
Table 2. Antimicrobial susceptibility trend of isolates cultured from urine of ICU patients (2016-2017)

| S. N. | Gender | Isolate                  | Susceptible to | Resistant to |
|-------|--------|--------------------------|----------------|--------------|
| 1     | Male   | *Pseudomonas aeruginosa* | Ak, Ca, Cf, Cx, G, Mm, PT | A, AC, Ci, CN, Nf, TS, Tg, Im |
| 2     | Male   | *Escherichia coli*       | AC, A, Ci, Cf, Cl, Cx, G, Im, Mm, Mm, TS, Tg, PT | A, AC, Ci, CN, Nf, TS, Tg, Im |
| 3     | Male   | *Escherichia coli*       | A, AC, Ak, Ca, Cx, Cl, Cx, Cx, G, Im, Mm, Mm, TS, Tg, PT | A, AC, CF, TS |
| 4     | Male   | *Klebsiella pneumoniae*  | G              | A, AC, Ca, Cf, Cl, Cx, Cx, G, Im, Mm, Mm, TS, Tg, Im |
| 5     | Female | *Klebsiella pneumoniae*  | AC, Ak, Ca, Cl, Cx, Cx, Cx, G, Im, Mm, Mm, TS, Tg, PT | A, AC, Cl, Cn, Nf, TS, Tg, Ca, Im |
| 6     | Female | *Serratia marcescens*    | Ca, Cf, Cx, Cx, Mm, Mm, TS, Tg, PT | A, AC, Cl, CN, Nf, TS, Tg, AK, CN |
| 7     | Female | *Escherichia coli*       | Ca, Cx, Cl, Cx, Cx, Cx, Mm, Mm, TS, Tg, PT | A, AC, Cl, CN, Nf, TS, Tg, AK, CN |
| 8     | Female | *Acinetobacter baumannii C.* | A, AC, Ak, Ca, Cl, Cx, Cx, G, Im, Mm, Mm, TS, Tg, PT | A, AC, Cl, CN, Nf, TS, Tg, AK, CN |
| 9     | Female | *Escherichia coli*       | AK, Ca, Cf, Cx, G, Im, Mm, TS, Tg, PT | A, AC, AK, CA, CF, CL, Cx, Cx, CN, NF, Mm, Mm, TS, PT, AK, IM, TG |
| 10    | Female | *Enterococcus faecalis*  | A, Cl, CN, NF, TS, TG | A, AC, AK, CA, CF, CL, Cx, Cx, CN, NF, Mm, TS, PT, AK, IM, TG |
| 11    | Female | *Pseudomonas aeruginosa* | AK, Ca, CF, G, Pt | A, AC, AK, CL, CN, NF, TS, TG, CA, IM |
| 12    | Female | *Enterococcus faecalis*  | A, Cl, NF, LF, Lx, NF, MG, VA | A, AC, AK, CL, CN, NF, TS, TG |
| 13    | Female | *Acinetobacter baumannii C.* | AK, CA, CF, Cx, G, Im, Mm, TS, Tg, PT | A, AC, AK, CL, CN, NF, TS, TG |
| 14    | Female | *Escherichia coli*       | CA, CF, CX, CL, Cx, Cx, G, Im, Mm, TS, Tg, PT | A, AC, AK, CL, CN, NF, TS, TG |
| 15    | Female | *Acinetobacter baumannii C.* | A, AC, CF, G, Im, Mm, TS, Tg, PT | A, AC, AK, CL, CN, NF, TS, TG |
| 16    | Female | *Escherichia coli*       | A, AC, CF, G, Im, Mm, TS, Tg, PT | A, AC, AK, CL, CN, NF, TS, TG |
| 17    | Male   | *Enterobacter cloacae dissolvens* | A, AC, CF, Cx, G, Im, Mm, TS, Tg, PT | A, AC, AK, CL, CN, NF, TS, TG |
| 18    | Male   | *Pseudomonas aeruginosa* | AK, Ca, CF, Cx, G | A, AC, AK, CA, CF, CL, Cx, CN, NF, Mm, TS, TG, PT |
| 19    | Male   | *Pseudomonas aeruginosa* | AK, CA, CF, CF, CN, NF, G, Im, Mm, TS, TG, PT | A, AC, AK, CA, CN, NF, Mm, TS, TG, PT |
| 20    | Male   | *Enterococcus faecalis*  | A, Cl, NF, LF, Lx, NF, MG, VA | A, AC, AK, CL, CN, NF, TS, TG |
| 21    | Male   | *Acinetobacter baumannii C.* | AK, CA, CF, Cx, G, Im, Mm, TS, Tg, PT | A, AC, AK, CL, CN, NF, TS, TG |
| 22    | Male   | *Escherichia coli*       | A, AC, Ak, Cl, Cx, Cx, Cx, G, Im, Mm, Mm, TS, Tg, PT | A, AC, AK, CL, CN, NF, TS, TG |
| 23    | Male   | *Escherichia coli*       | A, AC, Ak, Cl, Cx, Cx, Cx, G, Im, Mm, Mm, TS, Tg, PT | A, AC, AK, CL, CN, NF, TS, TG |
| 24    | Male   | *Escherichia coli*       | A, AC, Ak, Cl, Cx, Cx, Cx, G, Im, Mm, Mm, TS, Tg, PT | A, AC, AK, CL, CN, NF, TS, TG |
| 25    | Male   | *Acinetobacter baumannii C.* | A, AC, CF, Cx, G, Im, Mm, Mm, TS, Tg, PT | A, AC, AK, CL, CN, NF, TS, TG |
| 26    | Male   | *Enterococcus cloacae*   | A, AC, CF, Cx, G, Im, Mm, Mm, TS, Tg, PT | A, AC, AK, CL, CN, NF, TS, TG |
| 27    | Female | *Escherichia coli*       | A, AC, AK, CA, CF, Cl, Cx, Cx, CN, NF, G, Im, Mm, TS, TG, PT | A, AC, AK, CL, CN, NF, TS, TG |
| 28    | Female | *Escherichia coli*       | A, AC, AK, CA, CF, Cl, Cx, Cx, CN, NF, G, Im, Mm, TS, TG, PT | A, AC, AK, CL, CN, NF, TS, TG |
| 29    | Female | *Acinetobacter baumannii C.* | None | A, AC, AK, CA, CF, Cl, Cx, Cx, CN, NF, G, Im, Mm, TS, TG, PT |
| 30    | Male   | *Acinetobacter baumannii C.* | TS, CI | A, AC, AK, CL, CN, NF, TS, TG, PT |
| 31    | Female | *Enterobacter cloacae*   | A, AC, AK, CF, G, Im, Mm, Mm, TS, TG, TS | A, AC, CN, CA, CI, PT |
| 32    | Female | *Escherichia coli*       | A, AC, AK, CF, G, Im, Mm, Mm, TS, TG, TS | A, AC, CN, CA, CI, PT |
| 33    | Female | *Proteus mirabilis*      | A, AC, AK, CF, G, Im, Mm, Mm, TS, TG, TS | A, AC, CN, CA, CI, PT |
| 34    | Male   | *Escherichia coli*       | A, AC, AK, CF, G, Im, Mm, Mm, TS, TG, TS | A, AC, CN, CA, CI, PT |
| 35    | Female | *Acinetobacter baumannii C.* | CG, TS, TG | A, AC, AK, CF, G, Im, Mm, Mm, TS, TG, TS |
| 36    | Male   | *Pseudomonas aeruginosa* | AK, CF, G, PT | A, AC, AK, CN, CF, G, Im, Mm, Mm, TS, TG, TS (ESBL +ve), IM, MM |
| 37    | Male   | *Klebsiella pneumoniae*  | IM, MM | A, AC, AK, CN, CF, G, Im, Mm, Mm, TS, TG, TS (ESBL +ve), IM, MM |
culturated from blood of ICU admitted patients, *Enterobacteriaceae* (36.8%) was the most common pathogen. Coagulase negative Staphylococci (CoNS) among Gram-positive bacteria were cultured from 34.2% of the subjects. Recent research studies have indicated *Pseudomonas* spp., *Acinetobacter* spp., *Escherichia coli* and *Klebsiella* spp. to be the most common pathogens in ICU-acquired infections.\[15,17\].

Ceftazidime and aztreonam are loosing their activity against the Gram-negative microorganisms. The fourth generation cephalosporins have an intrinsic high activity against the inducible *Enterobacteriaceae*. The introduction of ceftazidime for nosocomial infections led to a remarkable drop in the number of *Enterobacter* isolates combined with important decreases in *Enterobacter* resistance towards several antibiotics. Prescribing antibiotics is therefore an important task. Concentrating sick people in crowded spaces leads to an increase in the incidence of infections.\[18\].

Infections acquired in the ICU are associated with microbiological isolates different from those acquired in the community, and are often associated with resistant organisms. Further evidence suggested an algorithm regarding antibiotic initiation for patients in the ICU (Fig. 8)\[1\].

The UAE AMR National Surveillance Report stated that, *E. coli* was the most common pathogen of BSIs followed by *K. pneumoniae* and *S. aureus*. However, their study showed that *K. pneumoniae* showed a resistance of 37% against ceftriaxone and 12% against carbapenems.\[2\].

From the Global Antimicrobial Surveillance System, World Health Organization (GLASS-WHO) study, *E. coli* is the dominant agent causing UTIs and *K. pneumoniae* is the leading cause of BSIs followed by *E. coli*. The common finding between our study and GLASS-WHO is that, *E. coli* displays the highest resistance to Ampicillin. In addition, the resistance is very low for carbapenems namely, imipenem and meropenem.\[3\].

In support to our study, their study found that *K. pneumoniae* from urine samples displays high resistance to ceftriaxone in blood and urine. In addition, the agent shows equal proportion of resistance to ceftazidime, cefotaxime and cotrimoxazole. Lastly, the resistance profile is very
low vis-a-vis urine cultures against carbapenems, (imipenem and meropenem)\textsuperscript{1}.

In our study, among the isolates cultured from urine of ICU admitted patients, \textit{Enterobacteriaceae} (46.6\%) was the most common pathogen. Non-fermenter Gram-negative bacteria were present at 38.4\%. \textit{Enterococcus faecalis} was the only Gram-positive pathogen cultured from urine.

Venkataraman et al., found isolates of \textit{Klebsiella} spp., \textit{E. coli}, \textit{Acinetobacter} spp., and \textit{Pseudomonas} spp., to be resistant to the 3rd generation cephalosporins. They found around 70\% isolates to be resistant to all the antibiotics tested. They attributed this resistance to use of 3rd generation cephalosporins for already received empiric treatment, which induces antibiotic resistance\textsuperscript{15,19}.

Of late, in all hospital settings including ICUs the antibiotic resistance has escalated worldwide. This is responsible for inappropriate and delayed prescription that further leads to high mortality rates\textsuperscript{20}. Tumbarello et al., stated BSIs caused by extended-spectrum β-lactamase (ESBL)-producers leads to 3-fold increase in mortality\textsuperscript{21}. In our study, among \textit{K. pneumoniae} isolated from blood a resistance rate of 85.7\% was observed against ampicillin and ceftriaxone. The isolates of \textit{K. pneumoniae} were uniformly resistant (50-75\% resistant) to range of antibiotics tested, including ciprofloxacin, trimethoprim-sulphamethoxazole amikacin, ceftoxin, ceftazidime, ceftriaxone, cefepime, nitrofurantoin, imipenem, meropenem and β-lactam plus β-lactamase inhibitor combinations (amoxiclave and piperacillin-tazobactam).

Interestingly, 85.7\% \textit{K. pneumoniae} were susceptible to a conventional antibiotic, gentamicin. It was alarming to notice 42.9\% resistance to tigecycline.

\textit{E. coli} isolated from urine were 100\% susceptible to carbapenems (imipenem and carbapenem). Isolates ranged 50-75\% in resistance to array of antibiotics tested. Of the isolates, 91.75\% were susceptible to tigecycline.

\textit{P. aeruginosa} isolates cultured from urine of ICU patients were 100\% resistant to ampicillin, amoxicillin-clavulanate, ceftriaxone, ceftoxin, and trimethoprim-sulphamethoxazole. Interestingly, 100\% isolates were susceptible to gentamicin; and 90\% susceptible to cefepime and nitrofurantoin. For other range of antibiotics tested, the resistance rate varied from 50\% to 75\%.

\textit{K. pneumoniae} isolates cultured from urine of ICU patients uniformly displayed 75\% resistance to ciprofloxacin, ceftriaxone, cefoxitin and cefepime. Overall, 87.5\% of \textit{K. pneumoniae} were resistant to nitrofurantoin. Further, 75\% of \textit{K. pneumoniae} were susceptible to gentamicin.

A. baumannii complex cultured from urine of ICU patients displayed an alarmingly high rate of consistent resistance to all the antibiotics tested. Further, the isolates were 50-75\% susceptible only to selective antibiotics such as, gentamicin, imipenem, meropenem, and tigecycline.

The EUROBACT study demonstrated the role of MDR Gram-negative pathogens in more than 50\% cases in ICUs\textsuperscript{22}. BSIs caused by ESBLs is a major challenge for clinicians. The randomized clinical trials have not demonstrated the effectiveness of β-lactam/β-lactamase inhibitor combinations (such as piperacillin-tazobactam). In critically ill patients, carbapenems are used as the first drug of choice\textsuperscript{23}. Due to this overuse and misuse, antibacterial resistance to carbapenem has gradually increased. Carbapenem resistance in Europe, among hospital acquired BSI causing pathogens, such as, \textit{Acinetobacter} spp., \textit{K. pneumoniae} and \textit{Pseudomonas} spp. has been shown to be around 69\%, 37\% and 5.7\% respectively\textsuperscript{22}.

Very few options for treating carbapenem-resistant pathogens are available now. The use of combination antibiotics including tigecycline or colistin along with a carbapenem have been preferred due to its benefit over observational monotherapy studies\textsuperscript{21}. Unfortunately, pathogens, which are multi-drug resistant (MDR), are often resistant to many other antibiotics such as aminoglycosides and fluoroquinolones. Further, colistin resistance has become common among MDR Gram-negative pathogens\textsuperscript{24}.

Results from a single-center study varies compared to multicenter study, since the patients from a single hospital may have different risk factors, severity of infection, and use of invasive devises\textsuperscript{16}. Length of stay in hospital is an important reason for the development of infection\textsuperscript{15}. Longer
stay necessitates longer period of insertion of devices and chances of colonization with MDR pathogens.

CONCLUSION
Coliforms (K. pneumoniae in BSI; E. coli in UTI) happen to be the prominent pathogens in our ICU admitted patients. K. pneumoniae isolated from blood demonstrated 50-75% resistance to a range of antibiotics tested - amikacin, ceftazidime, ciprofloxacin, cefepime, nitrofurantoin, imipenem, meropenem and beta-lactam+beta-lactamase inhibitor combinations. It was alarming to notice 42.9% resistance to tigecycline among K. pneumoniae isolated from blood. K. pneumoniae isolates cultured from urine of ICU patients uniformly displayed 75% rate of resistance to ciprofloxacin, ceftriaxone, cefoxitin and cefepime. Overall, 87.5% of K. pneumoniae were resistant to nitrofurantoin. Interestingly, it is of relief to observe 85.7% Klebsiella pneumoniae isolated from blood and 75% K. pneumoniae isolated from urine being susceptible to a conventional antibiotic, gentamycin. E. coli isolated from urine were 100% susceptible to carbapenems (imipenem and carbapenem) and 91.75% susceptible to tigecycline. Overall, 90% of P. aeruginosa were susceptible to nitrofurantoin. Overall, a resistance rate of 50-75% was observed against the range of antibiotics. The rapid spread of these MDR pathogens demands for national and regional guidelines. Antimicrobial guidelines for empirical treatment and to treat infections in ICUs should be designed based on local microbiological data and resistance profiles of pathogens. Infection prevention & control (IPC) measures should be in place for reducing the spread of antimicrobial resistant pathogens. These measures can prevent further infections and AMR spread.

ACKNOWLEDGMENTS
We would like to acknowledge the Central Research Laboratory (CRL) facility of RAK Medical & Health Sciences University (RAKMHSU), Ras Al Khaimah, UAE.

CONFLICT OF INTEREST
The authors declare that there is no conflict of interest.

AUTHORS’ CONTRIBUTION
All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

FUNDING
None.

ETHICS STATEMENT
This study was approved by RAKMHSU-REC and RAK-REC committees.

DATA AVAILABILITY
All datasets generated or analyzed during this study are included in the manuscript.

REFERENCES
1. Denny KJ, Wale J De, Laupland KB, Harris PNA, Lipman J. When not to start antibiotics: avoiding antibiotic overuse in the intensive care unit. Clin Microbiol Infect. 2020;26:35-40. doi: 10.1016/j.cmi.2019.07.007
2. Thomsen J, Abdulrazzaq N. United Arab Emirates national surveillance system for antimicrobial resistance, 2019. https://www.escmid.org/escmid_publications/escmid_elibrary/material/?mid=67722.
3. World Health Organization. Global Antimicrobial Resistance Surveillance System (GLASS). 2019;216-219.
4. Mnatzaganian G, Galai N, Sprung CL, et al. Increased risk of bloodstream and urinary infections in intensive care unit (ICU) patients compared with patients fitting ICU admission criteria treated in regular wards. J Hosp Infect. 2005;59(4):331-342. doi: 10.1016/j.jhin.2004.07.028
5. Bassetti M, Righi E, Alessia Carnielutti. Bloodstream infections in the Intensive Care Unit, Virulence. 2016;7:267-279. doi: 10.1080/21505594.2015.1134072
6. Nasa P, Juneja D, Singh O, et al. Incidence of bacteremia at the time of ICU admission and its impact on outcome. Indian J Anaesth. 2011;55(6):594-598. doi: 10.4103/0019-5049.90615
7. Ammerlaan HSM, Harbarth S, Buiting AGM, et al. Secular trends in nosocomial bloodstream infections: antibiotic-resistant bacteria increase the total burden of infection. Clinical Infect Dis. 2013;56(6):798-805. doi: 10.1093/cid/cis1006
8. Magiorakos A-P, Srinivasan A, Carey R, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268-281. doi: 10.1111/j.1469-0691.2011.03570.x
9. Carlet J, Collignon P, Goldmann D, et al. Society’s failure to protect a precious resource: antibiotics. Lancet. 2011;378(9788):369-371. doi: 10.1016/S0140-6736(11)60401-7
10. Russotto V, Cortegiani A, Graziano G, et al. Bloodstream
infections in intensive care unit patients: distribution and antibiotic resistance of bacteria. *Infect Drug Resist.* 2015;8:287-296. doi: 10.2147/IDR.S48810

11. Jaggi N, Sissodia P. Multimodal supervision programme to reduce catheter associated urinary tract infections and its analysis to enable focus on labour and cost effective infection control measures in a tertiary care hospital in India. *J Clin Diagn Res.* 2012;6(8):1372-1376. doi: 10.7860/JCDR/2012/4229.2362

12. Silver SA, Baillie L, Simor AE. Positive urine cultures: A major cause of inappropriate antimicrobial use in hospitals. *Can J Infect Dis Med Microbiol.* 2009;20:107-111. doi: 10.1155/2009/702545

13. Gastmeier P, Sohr D, Just HM, et al. How to survey nosocomial infections. *Infect Control Hosp Epidemiol.* 2000;21(6):366-370. doi: 10.1086/501774

14. Rosenthal VD, Maki DG, Salomao R, et al. Device-associated nosocomial infections in 55 Intensive Care Units of 8 developing countries. *Ann Intern Med.* 2006;145(8):582-591. doi: 10.7326/0003-4819-145-8-200610170-00007

15. Habibi S, Wig N, Agarwal S, et al. Epidemiology of nosocomial infections in medicine intensive care unit at a tertiary care hospital in Northern India. *Trop Doct.* 2008;38:233-235. doi: 10.1258/td.2008.070395

16. Richards MJ, Edwards JR, Culver DH, et al. Nosocomial infections in combined medical-surgical Intensive Care Units in the United States. *Infect Control Hosp Epidemiol.* 2000;21(8):510-515. doi: 10.1086/501795

17. Kamat US, Ferreira AMA, Savio R, Motghare DD. Antimicrobial resistance among nosocomial isolates in a teaching hospital in Goa. *Indian J Community Med.* 2008;33(2):89-92. doi: 10.4103/0970-0218.40875

18. Demy HE, Jansens H, Laer FV, leven M, Goossens H, Bossaert LL. Strategies for selecting antibiotics in intensive care units. *Clin Microbiol Infect.* 1999;5(S1):S29-S34. doi: 10.1111/j.1469-0691.1999.tb00722.x

19. Venkatakrishnan R, Divatia JV, Ramakrishnan N, et al. Multicenter observational study to evaluate epidemiology and resistance patterns of common intensive care unit-infections. *Indian J Crit Care Med.* 2018;22:20-26. doi: 10.4103/ijccm.IJCCM_394_17

20. Ammerlaan HSM, Harbarth S, Buiting AGM, et al. Secular trends in nosocomial bloodstream infections: Antibiotic-resistant bacteria increase the total burden of infection. *Clin Infect Dis.* 2013;56:798-805. doi: 10.1093/cid/cis1006

21. Tumbarello M, Sanguinetti M, Montuori E, et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing *Enterobacteriaceae*: Importance of inadequate initial antimicrobial treatment. *Antimicrob Agents Chemother.* 2007;51:1987-1994. doi: 10.1128/AAC.01509-06

22. Tabah A, Koulenti D, Laupland K, et al. Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: The EUROCABT International Cohort Study. *Intensive Care Med.* 2012;38:1930-1945. doi: 10.1007/s00134-012-2695-9

23. Harris PN, Tambyah PA, Paterson DL. β-lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum β-lactamase producing *Enterobacteriaceae*: Time for a reappraisal in the era of few antibiotic options? *Lancet Infect Dis.* 2013;15(4):475-485. doi: 10.1016/S1473-3099(14)70950-8

24. Bassetti M, Righi E. SDD and colistin resistance: End of a dream? *Intensive Care Med.* 2014;40:1066-1067. doi: 10.1007/s00134-014-3328-2